Wolin D - Search Results

1

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.

Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Armstrong AW, et al. Among authors: wolin d. Dermatol Ther (Heidelb). 2024 Feb;14(2):421-439. doi: 10.1007/s13555-023-01089-6. Epub 2024 Jan 22. Dermatol Ther (Heidelb). 2024. PMID: 38252376 Free PMC article.

2

Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab.

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Magrey M, et al. Among authors: wolin d. Clin Drug Investig. 2019 Dec;39(12):1205-1212. doi: 10.1007/s40261-019-00856-8. Clin Drug Investig. 2019. PMID: 31549346 Free PMC article.

3

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab.

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y. Magrey M, et al. Among authors: wolin d. Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/s40801-019-0154-4. Drugs Real World Outcomes. 2019. PMID: 31054047 Free PMC article.

4

Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey.

Brett Hauber A, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D. Brett Hauber A, et al. Among authors: wolin d. Support Care Cancer. 2018 Jan;26(1):251-260. doi: 10.1007/s00520-017-3841-2. Epub 2017 Aug 7. Support Care Cancer. 2018. PMID: 28785862

5

Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries.

Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Bröcker A, Tarenz C, Suzart-Woischnik K. Zografos L, et al. Among authors: wolin d. Expert Opin Drug Saf. 2022 Mar;21(3):435-446. doi: 10.1080/14740338.2022.1998451. Epub 2021 Nov 22. Expert Opin Drug Saf. 2022. PMID: 34806928

6

Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Zografos LJ, et al. Among authors: wolin dl. Pharmaceut Med. 2019 Jun;33(3):219-233. doi: 10.1007/s40290-019-00279-y. Pharmaceut Med. 2019. PMID: 31933286

7

Understanding Barriers in the Pathway to Diagnosis of Ankylosing Spondylitis: Results From a US Survey of 1690 Physicians From 10 Specialties.

Magrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Magrey M, et al. Among authors: wolin d. ACR Open Rheumatol. 2020 Oct;2(10):616-626. doi: 10.1002/acr2.11179. Epub 2020 Oct 7. ACR Open Rheumatol. 2020. PMID: 33029932 Free PMC article.

8

The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, Grattan C, Hollis K, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Nakonechna A, Ortiz de Frutos J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. Maurer M, et al. Among authors: wolin d. Allergy. 2017 Dec;72(12):2005-2016. doi: 10.1111/all.13209. Epub 2017 Jul 10. Allergy. 2017. PMID: 28543019 Free PMC article.

9

Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik K. Zografos LJ, et al. Among authors: wolin dl. Pharmaceut Med. 2024 Jan;38(1):63-73. doi: 10.1007/s40290-023-00506-7. Epub 2023 Dec 5. Pharmaceut Med. 2024. PMID: 38049618 Free PMC article.

10

Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Zografos LJ, et al. Among authors: wolin dl. Pharmaceut Med. 2019 Jun;33(3):235-246. doi: 10.1007/s40290-019-00278-z. Pharmaceut Med. 2019. PMID: 31933288

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page